biKEAP1 (compound 3) is an inhibitor that targets the KEAP1 dimer. By binding to cellular KEAP1 dimers, biKEAP1 releases the NRF2 protein that is sequestered by KEAP1, leading to the immediate activation of NRF2. This compound also promotes the nuclear translocation of NRF2 and directly inhibits the transcription of pro-inflammatory cytokines. biKEAP1 has demonstrated the ability to alleviate acute inflammation and reduce inflammatory damage in acute inflammation models.